April 22, 2019, Contemporary Clinic  

The first and only FDA-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral daily capsule for the treatment of moderate-to-severe vasomotor symptoms, BijuvaTM, from Therapeutics MD is now commercially available in the U.S., according to a press release from the company. Bijuva offers a proven balance of bio-identical estradiol combined with bio-identical progesterone to reduce risk to the endometrium in women with a uterus, according to the release. 

Read more.